China Medical first fiscal quarter net revenues increase 27.4% to US$36.7 million

China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, announced its unaudited financial results for the first fiscal quarter ended June 30, 2011 ("1Q FY2011") today.

"We have recently implemented the first steps of two new initiatives which will support our long term growth," commented Mr. Xiaodong Wu, Chairman and Chief Executive Officer of the Company. "We have established a collaboration with Da An Health for our domestic market as well as a collaboration with Leica Microsystems for both the domestic and the international markets. Da An Health is a fast growing independent laboratory service network serving mainly small and mid-size hospitals in China. We believe this collaboration will help us penetrate over time a new and big customer group for our molecular diagnostic products in a cost effective way. The collaboration with Leica Microsystems is to implement our strategy to enter the international market for our products through partnerships with leading global players. The partnership with Leica Microsystems substantially reduces our business risks and costs associated with entering the international market considering the complicated regulatory approval processes, medical reimbursement conditions and distribution channels in different countries and regions. The joint research and development with Leica Microsystems to automate our FISH probes on Leica's BOND system is important for the high volume users such as independent laboratory service networks in major global markets as well as existing and potential high volume hospital users in China. We are working closely with our new partners to realize the value of these collaborations for all of us. Meanwhile, we are also in discussion with a number of leading global players for different types of collaborations for our other molecular diagnostic products."

"Our DSO increased in recent quarters due to slower payment from some of our ECLIA distributors and the change in our sales mix," commented Mr. Sam Tsang, Chief Financial Officer of the Company. "ECLIA distributors normally pay in about 3 months but some of them took longer time to pay in the past few quarters. Slower payments from distributors indicate a possible risk of bad debt, and we have recently taken measures to control this risk including lowering credit limit for certain slow paying distributors and control over the order fulfillment for these distributors according to their payments. Meanwhile, we are adding new distributors to diversify the risk. The change in sales mix relates to the increasing portion of our revenues from our molecular diagnostic products which we sell to hospitals directly. These hospitals normally pay us in 6 to 12 months and the bigger the hospital, the longer the payment cycle. However, we consider the risk of bad debt from these hospitals to be very low considering that they are tier 1 hospitals, have a strong financial position and are government-owned. Recently, we have increased compensation of our direct sales personnel based on collection from hospitals to increase incentive for collection. On the other hand, despite the increase in DSO in the past few quarters, we still generated sizeable cash flows from operations. We expect our DSO to become stable and decline in the coming quarters."

"We are confident in handling our convertible debts before maturity," further commented Mr. Sam Tsang. "The nearest maturity of convertible debts is approximately US$17 million in November this year which is a small amount considering our cash position of approximately US$192 million. The next maturity of approximately US$247 million of convertible debts will be in August 2013. We believe that our current cash position, our future free cash flows and our access to other sources of funds such as commercial banks in China will provide sufficient liquidity to pay off the debts before maturity. We have noticed that the debts have been trading at a substantial discount which is favorable to us."

1Q FY2011 Unaudited Financial Results

The Company reported net revenues of RMB237.1 million (US$36.7 million) for 1Q FY2011, representing a 27.4% increase from the corresponding period of FY2010.

The Company's revenues are currently generated from two segments, molecular diagnostic systems and immunodiagnostic systems. The molecular diagnostic system segment mainly includes FISH products and SPR products while the immunodiagnostic system segment consists of ECLIA products.

Molecular diagnostic system sales for 1Q FY2011 were RMB156.1 million (US$24.2 million), representing a 44.5% increase from the corresponding period of FY2010. The year-over-year increase was primarily due to the increase in usage of the Company's FISH probes by hospitals as well as the significant increase in sales of SPR-based HPV-DNA chips to hospitals during 1Q FY2011.

Immunodiagnostic system sales for 1Q FY2011 were RMB81.0 million (US$12.5 million), representing a 3.7% increase from the corresponding period of FY2010.

Gross margin was 62.9% for 1Q FY2011 which decreased year-over-year from 67.0% for the corresponding period of FY2010. The year-over-year decrease was primarily due to the reclassification of amortization of SPR intangible assets from operating expenses to cost of revenues after the commencement of sales of HPV-DNA chips in 2Q FY2010. Such factor was partially offset by the positive impact of more contribution from the sales of FISH probes and HPV-DNA chips which generate higher gross margin and a decrease in the number of free ECLIA analyzers provided to distributors and free SPR analyzers provided to hospitals. Non-GAAP gross margin was 83.1% for 1Q FY2011 which increased year-over-year from 79.1% for the corresponding period of FY2010. The year-over-year increase in non-GAAP gross margin was primarily due to more contribution from the sales of FISH probes and HPV-DNA chips and the decrease in free ECLIA analyzers and SPR analyzers as noted above.

Research and development expenses were RMB10.8 million (US$1.7 million) for 1Q FY2011, representing a 1.1% year-over-year increase. The year-over-year increase was primarily due to an increase in salaries of research personnel offset by a decrease in stock compensation expense. Non-GAAP research and development expenses were RMB9.7 million (US$1.5 million) for 1Q FY2011, representing a 5.3% year-over-year increase. The year-over-year increase was primarily due to the increase in salaries of research personnel.

Sales and marketing expenses were RMB23.3 million (US$3.6 million) for 1Q FY2011, representing a 27.4% year-over-year increase. Non-GAAP sales and marketing expenses were RMB23.0 million (US$3.6 million) for 1Q FY2011, representing a 26.5% year-over-year increase. The year-over-year increases were primarily due to an increase in direct sales efforts for molecular diagnostic systems.

General and administrative expenses were RMB22.6 million (US$3.5 million) for 1Q FY2011, representing a 10.1% year-over-year decrease. The year-over-year decrease was primarily due to a decrease in stock compensation expense. Non-GAAP general and administrative expenses were RMB16.3 million (US$2.5 million) for 1Q FY2011, representing a 1.4% year-over-year increase.

Interest expense on convertible notes was RMB33.3 million (US$5.2 million) for 1Q FY2011. Non-GAAP interest expense on convertible notes was RMB32.4 million (US$5.0 million) for 1Q FY2011. As of June 30, 2011, the Company's outstanding convertible notes of US$16.7 million, US$246.5 million and US$150.0 million in principal value bear interest at 3.5%, 4% and 6.25% per annum, respectively, and will mature in November 2011, August 2013 and December 2016, respectively.

Interest expense related to amortization of convertible notes issuance costs was RMB4.0 million (US$0.6 million) for 1Q FY2011.

Interest expense related to amortization of share lending costs was RMB2.3 million (US$0.4 million) for 1Q FY2011.

Other income was RMB4.8 million (US$0.7 million) for 1Q FY2011, representing a 88.9% year-over-year decrease. The significant year-over-year decrease was primarily due to a decrease in gain on repurchase of convertible notes.

Income tax expense was RMB29.3 million (US$4.5 million) for 1Q FY2011. The high effective tax rate was due to the fact that certain expenses of the Company such as stock compensation expense, amortization of acquired intangible assets and interest expense of convertible notes were not deductible for income tax purpose. In addition, the Company was required to accrue for withholding income tax on distributable earnings generated in China which the Company does not intend to permanently reinvest in China.

Net income was RMB35.7 million (US$5.5 million) for 1Q FY2011, representing a 6.1% increase from the corresponding period of FY2010. The year-over-year increase was primarily due to the increase in molecular diagnostic system sales offset by the decrease in gain on repurchase of convertible notes. Non-GAAP net income was RMB90.5 million (US$14.0 million) for 1Q FY2011, representing a 58.7% increase from the corresponding period of FY2010. The year-over-year increase was primarily due to the increase in molecular diagnostic system sales and other reasons mentioned above.

Earnings before interest, taxes, depreciation and amortization ("EBITDA") was RMB150.6 million (US$23.3 million) for 1Q FY2011, representing a 6.1% increase from the corresponding period of FY2010. The year-over-year increase was primarily due to the increase in molecular diagnostic system sales offset by the decrease in gain on repurchase of convertible notes.

Adjusted EBITDA was RMB154.3 million (US$23.9 million) for 1Q FY2011, representing a 46.7% increase from the corresponding period of FY2010. The increase was primarily due to increased sales in 1Q FY2011.

Stock compensation expense for 1Q FY2011 was RMB7.8 million (US$1.2 million), of which RMB0.2 million was allocated to cost of revenues, RMB1.0 million to research and development expenses, RMB0.3 million to sales and marketing expenses and RMB6.3 million to general and administrative expenses.

Amortization of acquired intangible assets for 1Q FY2011 was RMB47.7 million (US$7.4 million) which was all allocated to cost of revenues.

As of June 30, 2011, the Company's cash and cash equivalents were RMB1,239.5 million (US$191.8 million). Net cash generated from operating activities for 1Q FY2011 was RMB62.2 million (US$9.6 million). Net cash generated from investing activities for 1Q FY2011 was RMB96.7 million (US$15.0 million). Net cash used in financing activities for 1Q FY2011 was RMB41.6 million (US$6.4 million).

As of June 30, 2011, the Company's net accounts receivable was RMB565.1 million (US$87.4 million), representing an increase of 17.5% from the balance at March 31, 2011. The increase in net accounts receivable was primarily due to the increase in molecular diagnostic system sales to hospital customers which normally pay in 6 to 12 months and the slower payments from certain distributors of immunodiagnostic systems.

The Company evaluates the collectability of its accounts receivable based on the aging of account balances, collection history, credit quality of the customer and current economic conditions that may affect a customer's ability to pay. The Company has recognized an allowance for doubtful accounts in its consolidated financial statements. The allowance for doubtful accounts increased by RMB2.4 million (US$0.4 million) to RMB28.8 million (US$4.4 million) as of June 30, 2011 from RMB26.4 million as of March 31, 2011.

For the convenience of readers, certain RMB amounts have been translated into U.S. dollars at the rate of RMB6.4635 to US$1.00, the noon buying rate in New York City for cable transfers of RMB per U.S. dollar as set forth in the H.10 weekly statistical release of the Federal Reserve Board, as of Thursday, June 30, 2011. No representation is made that the RMB amounts could have been or could be converted into U.S. dollars at that rate or at any other rate on June 30, 2011 or at any other dates.